Nurix Therapeutics Inc (NAS:NRIX)
$ 15.31 -0.59 (-3.71%) Market Cap: 934.95 Mil Enterprise Value: 754.30 Mil PE Ratio: 0 PB Ratio: 4.46 GF Score: 67/100

Nurix Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 20, 2023 / 07:00PM GMT
Release Date Price: $10.87 (-8.50%)
Gil Blum
Needham & Company - Analyst

Good afternoon, everyone, and thank you for joining me at the fourth day of the Needham & Company Healthcare Conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham and I cover the immuno-oncology and gene therapy subsectors. It is my pleasure to have with me today Nurix's CEO, Dr. Arthur Sands.

As a reminder, any viewers who are watching through our conference portal are able to submit questions via the Ask a Question box below the video feed window.

Questions & Answers

Gil Blum
Needham & Company - Analyst

So Arthur, maybe a good place to start just as an overview, provide some introductory remarks on Nurix. And not everyone is familiar with protein degradation, but what is it and how is Nurix doing it different?

Arthur Sands
Nurix Therapeutics, Inc. - President & CEO

Certainly. And first off, thanks, Gil, and thanks to the Needham team for hosting us. So targeted protein degradation, I can dive in and say one of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot